2023 AACR Public Disclosures

The molecules presented are investigational. Safety and efficacy have not been established.

BL-B01D1, a novel EGFR×HER3-targeting ADC, demonstrates robust anti-tumor efficacy in preclinical evaluation

BL-M07D1, a novel HER2-targeting ADC, demonstrates potent anti-tumor efficacy in preclinical pharmacodynamic models

BL-M02D1, a novel Trop2-targeting ADC, demonstrates robust anti-tumor efficacy in preclinical evaluation

Tetra-specific antibody GNC-035: guidance and navigation control (GNC) molecule development for treatment of ROR1+ malignancies

Tetra-specific antibody GNC-039: guidance and navigation control (GNC) molecule development for treatment of EGFRvIII+ malignancies

Tetra-specific antibody GNC-038: guidance and navigation control (GNC) molecule development for treatment of CD19+ malignancies

Anti-tumor efficacy of SI-B001, a novel EGFR×HER3 bispecific antibody, against EGFR-driven epithelial tumors alone or in combination with paclitaxel and carboplatin